- Nebraska Oncology Society
- The Nebraska Chapter of the American College of Cardiology
- Nebraska Rheumatology Society
- Medication-Assisted Treatment
- Nebraska Dermatology Society
- Nebraska Neurological Society
- Nebraska Radiological Society
- Nebraska Association of Pathologists
- Events

Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
10 seconds
Playback speed
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
2020 ASCO Updates on R/R Myeloma: Does FDA-Approved Selinexor Offer Survival Benefit? What Are the Response Rates With Teclistamab?
By
Nebraska Oncology Society
FEATURING
Adam D. Cohen
By
Nebraska Oncology Society
FEATURING
Adam D. Cohen
335 views
October 12, 2020
Comments 1
Login to view comments.
Click here to Login
Nebraska Oncology Society